Sanofi Drops Amlitelimab: Second OX40L Eczema Failure

Sanofi (SNY) announced on July 24, 2026 that it will discontinue clinical development of amlitelimab in moderate-to-severe atopic dermatitis, deciding the drug would not represent a meaningful improvement over the current standard of care despite positive Phase 3 long-term extension data. The company will not submit the drug for global regulatory reviews.

SNY closed at $43.35 on July 24 with volume of 3.07 million shares.

What was killed

Amlitelimab is an OX40-ligand monoclonal antibody that blocks T-cell-mediated inflammation without depleting T-cells. The mechanism was once considered a potential next-wave approach to autoimmune disease. Sanofi acquired the asset through its $1.1 billion Kymab acquisition in 2021.

Phase 3 ESTUARY long-term extension data showed patients aged 12 and older maintained clinical response without relapse. The drug worked. But Sanofi concluded the efficacy and safety profile was not enough to justify a filing in a crowded eczema market dominated by its own Dupixent (dupilumab), which generated over $13 billion in 2025 revenue.

The OX40L class signal

Sanofi’s decision follows Kyowa Kirin’s discontinuation of rocatinlimab, another OX40L inhibitor, in atopic dermatitis. Two OX40L programs now shelved in the same indication suggests a class-level problem: the mechanism may not differentiate sufficiently from existing IL-4/IL-13 biologics like Dupixent.

The safety angle matters here. OX40L inhibitors modulate T-cell co-stimulation, which theoretically carries immunomodulatory risks distinct from cytokine-blocking biologics. While Sanofi reported no significant safety concerns in the ESTUARY long-term extension, the commercial risk is more pressing: Dupixent’s $13 billion revenue and entrenched formulary position leave little room for a me-too entrant that does not offer clear efficacy superiority.

This is a cautionary data point for investors evaluating pipeline depth. A drug can hit its endpoints and still not be worth filing if the competitive bar has moved.

What survives

A Phase 2 study of amlitelimab in celiac disease remains ongoing, with data expected in the second half of 2026. If that fails too, the asset is effectively dead. The celiac indication is a smaller market but has far fewer competing therapies, which could lower the efficacy bar for filing. Celiac disease also has no approved therapies, meaning any drug demonstrating meaningful benefit could capture the entire market. The OX40L mechanism may still find a niche in a less crowded indication where the efficacy bar is lower than in eczema, where Dupixent and Ebglyss have set a high standard.

What to watch next

Watch for Sanofi’s pipeline update at its next earnings call. The discontinuation reflects a broader strategic review under new CEO leadership. Sanofi said as recently as March that amlitelimab showed potential to be a meaningful treatment option, making this a notable reversal worth tracking for further pipeline cuts.

Source: Sanofi press release | FierceBiotech coverage | See our guide on how to invest in biotech.